Potential drugs in COVID-19 management
- Фармація / Наукові статті / Англійською / Медицина
- Amin Gasmi/Sadaf Noor/Alain Menzel/Nataliia Khanyk/Yuliya Semenova/Roman Lysiuk/Nataliya Beley/Liliia Bolibrukh/Asma Gasmi Benahmed/Olha Storchylo/Geir Bjørklund
-
Співавтори:
-
Науковий керівник / консультант:
-
Голова СВР:
-
Опоненти:
-
Рецензенти:
-
Кафедра:
Кафедра соціальної медицини економіки та організації охорони здоров’я Львівського національного медичного університету імені Данила Галицького/Department of Social Medicine Economics and Health Care Organizations of Danylo Halytsky Lviv National Medical University -
НДР:
-
УДК:
-
Doi:
10.2174/0929867331666230717154101 -
ISBN:
- 8
The SARS-CoV-2 virus first emerged in China in December 2019 and quickly spread worldwide. Despite the absence of a vaccination or authorized drug specifically developed to combat this infection, certain medications recommended for other diseases have shown potential effectiveness in treating COVID-19, although without definitive confirmation. This review aims to evaluate the existing literature on the efficacy of these medications against COVID-19. The review encompasses various potential treatments, including antiviral medications, anti-malaria and anti-rheumatic drugs, vaccines, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), antipyretic and analgesic medicines, antiparasitic drugs, and statins. The analysis also addresses the potential benefits and drawbacks of these medications, as well as their effects on hypertension and diabetes. Although these therapies hold promise against COVID-19, further research, including suitable product production or clinical testing, is needed to establish their therapeutic efficacy.
Коментарів 0